Oral Diabetes Drugs - Revision history

Manikandan: /* Contact Dolcera */

2009-08-06T06:49:07Z

‎Contact Dolcera

Manikandan: /* Prevalence */

2009-08-06T06:48:47Z

‎Prevalence

Manikandan: /* Contact Dolcera */

2009-04-30T08:23:14Z

‎Contact Dolcera

Manikandan: /* Conference highlights for Oral Hypoglycemic Agents */

2009-04-30T08:04:01Z

‎Conference highlights for Oral Hypoglycemic Agents

Raiyani: /* Conferences */

2007-10-19T14:53:21Z

‎Conferences

Rajiv: /* Product Pathways */

2007-10-16T10:34:24Z

‎Product Pathways

Rajiv: /* Product pipeline */

2007-10-16T10:33:50Z

‎Product pipeline

Rajiv: /* Product pipeline */

2007-10-16T10:28:29Z

‎Product pipeline

Show changes

Vinod.singh@dolcera.com: /* Top players and IPC classes */

2007-09-14T17:19:47Z

‎Top players and IPC classes

Vinod.singh@dolcera.com: /* Geographical Distribution and Treatment Approaches */

2007-09-14T17:19:10Z

‎Geographical Distribution and Treatment Approaches

← Older revision		Revision as of 06:49, 6 August 2009
Line 1,096:		Line 1,096:


		+	==<span style="color:#C41E3A">Like this report?</span>==
		+	<p align="center"> '''This is only a sample report with brief analysis''' <br>
		+	'''Dolcera can provide a comprehensive report customized to your needs'''</p>
		+	{\|border="2" cellspacing="0" cellpadding="4" align="center" "
		+	\|style="background:lightgrey" align = "center" colspan = "3"\|'''[mailto:info@dolcera.com <span style="color:#0047AB">Buy the customized report from Dolcera</span>]'''
		+	\|-
		+	\| align = "center"\| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services Patent Analytics Services]
		+	\|align = "center"\| [http://www.dolcera.com/website_prod/services/business-research-services Market Research Services]
		+	\|align = "center"\| [http://www.dolcera.com/website_prod/tools/patent-dashboard Purchase Patent Dashboard]
		+	\|-
		+	\|align = "center"\| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/patent-search/patent-landscapes Patent Landscape Services]
		+	\|align = "center"\| [http://www.dolcera.com/website_prod/research-processes Dolcera Processes]
		+	\|align = "center"\| [http://www.dolcera.com/website_prod/industries Industry Focus]
		+	\|-
		+	\|align = "center"\| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/patent-search/patent-landscapes Patent Search Services]
		+	\|align = "center"\| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/alerts-and-updates Patent Alerting Services]
		+	\|align = "center"\| [http://www.dolcera.com/website_prod/tools Dolcera Tools]
		+	\|-
		+	\|}
		+	<br>
	==Contact Dolcera==		==Contact Dolcera==

@@ Line 52: / Line 52: @@
 |}
 ===Prevalence===
 The prevalence of diabetes( Both type I and type II ) in U.S. during the years 1980 to 2005, increased from 5.6 million to 15.8 million (Figure 4). Especially people aged from 65 to 74 had the highest prevalence compared to other age groups (Figure 5). The prevalence of the disease was similar in both men and women till the year 1998 but from 1999, the prevalence of the disease increased highly in men compared to females (Figure 6).

@@ Line 1,078: / Line 1,078: @@
 ==Contact Dolcera==
-'''Samir Raiyani'''
+{| style="border:1px solid #AAA; background:#E9E9E9" align="center"
+|-
-'''201 A South Delaware St. #306'''
+! style="background:lightgrey" | Samir Raiyani
-'''San Mateo, CA 94401 USA'''
+|-
-'''Phone: +1-650-269-7952'''
+| '''Email''': [mailto:info@dolcera.com info@dolcera.com]
-'''Fax: +1-866-690-7517'''
+|-
-'''info@dolcera.com'''
+| '''Phone''': +1-650-269-7952

← Older revision		Revision as of 08:04, 30 April 2009
Line 1,074:		Line 1,074:
	#[http://www.amylin.com/pipeline/symlin.cfm Amyline] analogue (Pramlinitide) was combined with Insulin for treatment of Type 2 DM and results were favorable.		#[http://www.amylin.com/pipeline/symlin.cfm Amyline] analogue (Pramlinitide) was combined with Insulin for treatment of Type 2 DM and results were favorable.
	# Continuous glucose monitoring using implanted glucose sensors is a step forward in evolving technology. Yet it is still very expensive and best for highly trained patients on intensive insulin therapy.		# Continuous glucose monitoring using implanted glucose sensors is a step forward in evolving technology. Yet it is still very expensive and best for highly trained patients on intensive insulin therapy.
		+
		+
		+	==Contact Dolcera==
		+
		+	'''Samir Raiyani'''
		+
		+	'''201 A South Delaware St. #306'''
		+	'''San Mateo, CA 94401 USA'''
		+	'''Phone: +1-650-269-7952'''
		+	'''Fax: +1-866-690-7517'''
		+	'''info@dolcera.com'''

@@ Line 1,060: / Line 1,060: @@
 * [http://www.conferencealerts.com/seeconf.mv?q=ca13a3h0 7th International Diabetes Federation Western Pacific Region Congress] at  Wellington, New Zealand on 30 Mar 2008.
 * [http://debussy.hon.ch/cgi-bin/confevent?aff2+CONF07692+Diabetes_Mellitus 1st International Conference on Advanced Technologies & Treatments for Diabetes] at Czech Republic during 27 Feb to 01 Mar 2008.
-* [http://www.goingtomeet.com/conventions/details/5301 Discovery Strategies Conference: Modeling Human Metabolic Syndrome and Type 2 Diabetes in Rodents] at Us during Aug-05-2007.
+* [http://www.goingtomeet.com/conventions/details/5301 Discovery Strategies Conference: Modeling Human Metabolic Syndrome and Type 2 Diabetes in Rodents] at US during Aug-05-2007.
 * [http://www.goingtomeet.com/conventions/details/15113 7th International Conference for Clinical Endocrinology,Diabetes and Infertility] at Egypt during Sep-06-2007.
 * [http://www.diabetes.ca/section_professionals/confindex.asp CDA/CSEM Professional Conference and Annual Meetings] at British Columbia during October 24-27, 2007.

← Older revision		Revision as of 10:34, 16 October 2007
Line 768:		Line 768:

	===Product Pathways===		===Product Pathways===
		+
		+	[[Image:Product_map.jpg\|thumb\|center\|900px\| Product]]
		+
		+	[[Image:Product-map.jpg\|thumb\|center\|900px\| Product pipeline]]

	==Intellectual Property==		==Intellectual Property==

← Older revision		Revision as of 10:33, 16 October 2007
Line 766:		Line 766:

	\|}		\|}
		+
		+	===Product Pathways===

	==Intellectual Property==		==Intellectual Property==

@@ Line 869: / Line 869: @@
 ===Top players and IPC classes===
-[[Image:Diabetes- top players.jpeg|center|850 px|]]
+[[Image:Diabetes- top players.jpeg|center|800 px|]]
 ====IPC code definition====

@@ Line 893: / Line 893: @@
 ===Geographical Distribution and Treatment Approaches===
-[[Image:Diabetes -geographical.jpeg|center|850 px|]]
+[[Image:Diabetes -geographical.jpeg|center|800 px|]]
 ===IP activity and Treatment Approaches===